24
Mar
The DCGI (Drug Controller General of India) approved TB drug, pretomanid, for conditional access under the National Tuberculosis Elimination Program (NTEP), can play a significant role towards elimination of highly drug-resistant TB in India Pretomanid is a ‘made in India’ product used as part of a six-month treatment regimen with reported efficacy of 90%; has potential to contribute to India’s ‘TB Elimination program by 2025’ New Delhi, India March 24: The world continues to battle against pandemics, including COVID-19 and tuberculosis (TB). March 24, marks World TB Day and TB Alliance, a global not-for-profit organization, is joining with partners around…
